164. Oculocutaneous albinism Clinical trials / Disease details


Clinical trials : 15 Drugs : 57 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 139

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01838655
(ClinicalTrials.gov)
April 16, 201320/4/2013Nitisinone for Type 1B Oculocutaneous AlbinismA Pilot Study of Nitisinone in the Treatment of Oculocutaneous Albinism, Type 1BAlbinism;Vision LossDrug: NitisinoneNational Eye Institute (NEI)National Human Genome Research Institute (NHGRI)Completed18 YearsN/AAll5Phase 1/Phase 2United States